Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Canada flag Canada · Delayed Price · Currency is CAD
0.7100
+0.0100 (1.43%)
Oct 1, 2025, 10:29 AM EDT
1.43%
Market Cap36.29M
Revenue (ttm)n/a
Net Income (ttm)-5.09M
Shares Out51.84M
EPS (ttm)-0.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume10,306
Open0.7100
Previous Close0.7000
Day's Range0.7100 - 0.7100
52-Week Range0.5100 - 0.8800
Beta0.65
RSI40.25
Earnings DateNov 17, 2025

About Thiogenesis Therapeutics

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Patrice Rioux
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol TTI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.